Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors

BACKGROUND: Immune checkpoint inhibitors (ICIs) have become established as a new therapeutic paradigm in various solid cancers. Predictive biomarkers to ICIs have not yet been fully established. Tumor mutational burden (TMB) has been considered as a useful marker to indicate patients who benefit fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hana, Hong, Jung Yong, Lee, Jeeyun, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Kim, Kyoung-Mee, Kim, Seung Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917846/
https://www.ncbi.nlm.nih.gov/pubmed/33717226
http://dx.doi.org/10.1177/1758835921992992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917846/
https://www.ncbi.nlm.nih.gov/pubmed/33717226
http://dx.doi.org/10.1177/1758835921992992

Ejemplares similares